Literature DB >> 28150129

Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.

Jada G Hamilton1,2, Margaux C Genoff3, Melissa Salerno4, Kimberly Amoroso4, Sherry R Boyar4,5, Margaret Sheehan4, Megan Harlan Fleischut4, Beth Siegel4, Angela G Arnold4, Erin E Salo-Mullen4, Jennifer L Hay3,6, Kenneth Offit4,7, Mark E Robson4,7.   

Abstract

PURPOSE: Women who are newly diagnosed with breast cancer may consider contralateral prophylactic mastectomy (CPM) to reduce their future risk of cancer in their unaffected breast. Pre-surgical BRCA1/2 genetic testing can provide valuable risk information to guide this choice. However, little is understood about why BRCA1/2 mutation noncarriers, who are generally not at substantially elevated risk of contralateral disease, select CPM.
METHODS: We examined the uptake of CPM among breast cancer patients identified as BRCA1/2 mutation noncarriers (n = 92) as part of a larger prospective study of the impact of pre-surgical BRCA1/2 testing. Data obtained from self-report questionnaires and patient medical records were used to examine associations between theoretically relevant background and psychosocial factors and BRCA1/2 mutation noncarriers' decisions to undergo CPM.
RESULTS: Among BRCA1/2 mutation noncarriers, 25% (n = 23) elected to undergo CPM. Psychosocial factors including a self-reported physician recommendation for CPM, greater perceived contralateral breast cancer risk, and greater perceived benefits of CPM were all significantly associated with the uptake of CPM.
CONCLUSIONS: A sizeable minority of BRCA1/2 mutation noncarriers choose to undergo CPM after learning their mutation status through pre-surgical genetic testing. BRCA1/2 mutation noncarriers' cognitive perceptions and social influences appear to be important in shaping their decisions regarding CPM. This work highlights the importance of several psychosocial factors in influencing patients' surgical decisions. Future research is needed that examines the formation of BRCA1/2 mutation noncarriers' beliefs regarding their disease and available treatment options, and that characterizes the physician-patient communication that occurs in this complex decision-making context.

Entities:  

Keywords:  Breast cancer; Decision-making; Genetic testing; Prevention; Prophylactic mastectomy

Mesh:

Year:  2017        PMID: 28150129      PMCID: PMC5329117          DOI: 10.1007/s10549-017-4123-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  41 in total

1.  BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.

Authors:  Shoshana M Rosenberg; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Lidia Schapira; Steven Come; Virginia F Borges; Bryce Larsen; Judy E Garber; Ann H Partridge
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

2.  Risk, worry and cosmesis in decision-making for contralateral risk-reducing mastectomy: analysis of 60 consecutive cases in a specialist breast unit.

Authors:  H Beesley; C Holcombe; S L Brown; P Salmon
Journal:  Breast       Date:  2012-06-29       Impact factor: 4.380

3.  Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance.

Authors:  Marlene H Frost; Jeffrey M Slezak; Nho V Tran; Constance I Williams; Joanne L Johnson; John E Woods; Paul M Petty; John H Donohue; Clive S Grant; Jeff A Sloan; Thomas A Sellers; Lynn C Hartmann
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

4.  Nationwide trends in mastectomy for early-stage breast cancer.

Authors:  Kristy L Kummerow; Liping Du; David F Penson; Yu Shyr; Mary A Hooks
Journal:  JAMA Surg       Date:  2015-01       Impact factor: 14.766

5.  Redefining Risk and Benefit: Understanding the Decision to Undergo Contralateral Prophylactic Mastectomy.

Authors:  Katharine A S Rendle; Meghan C Halley; Suepattra G May; Dominick L Frosch
Journal:  Qual Health Res       Date:  2014-11-04

6.  Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.

Authors:  Mark Robson; Tiffany Svahn; Beryl McCormick; Patrick Borgen; Clifford A Hudis; Larry Norton; Kenneth Offit
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

7.  Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States.

Authors:  Reshma Jagsi; Jing Jiang; Adeyiza O Momoh; Amy Alderman; Sharon H Giordano; Thomas A Buchholz; Steven J Kronowitz; Benjamin D Smith
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

8.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  Modeling adherence to colorectal cancer screening.

Authors:  R E Myers; E Ross; C Jepson; T Wolf; A Balshem; L Millner; H Leventhal
Journal:  Prev Med       Date:  1994-03       Impact factor: 4.018

10.  Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.

Authors:  Anne S Reiner; Esther M John; Jennifer D Brooks; Charles F Lynch; Leslie Bernstein; Lene Mellemkjær; Kathleen E Malone; Julia A Knight; Marinela Capanu; Sharon N Teraoka; Patrick Concannon; Xiaolin Liang; Jane C Figueiredo; Susan A Smith; Marilyn Stovall; Malcolm C Pike; Robert W Haile; Duncan C Thomas; Colin B Begg; Jonine L Bernstein
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

View more
  6 in total

1.  Longitudinal Study of Psychosocial Outcomes Following Surgery in Women with Unilateral Nonhereditary Breast Cancer.

Authors:  David W Lim; Helene Retrouvey; Isabel Kerrebijn; Kate Butler; Anne C O'Neill; Tulin D Cil; Toni Zhong; Stefan O P Hofer; David R McCready; Kelly A Metcalfe
Journal:  Ann Surg Oncol       Date:  2021-04-05       Impact factor: 5.344

2.  Analysis of a Trend Reversal in US Lumpectomy Rates From 2005 Through 2017 Using 3 Nationwide Data Sets.

Authors:  Jonas A Nelson; Robyn N Rubenstein; Kathryn Haglich; Jacqueline J Chu; Shen Yin; Carrie S Stern; Monica Morrow; Babak J Mehrara; Mary L Gemignani; Evan Matros
Journal:  JAMA Surg       Date:  2022-08-01       Impact factor: 16.681

3.  Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.

Authors:  Mara Tynan; Beth N Peshkin; Claudine Isaacs; Shawna Willey; Heiddis B Valdimarsdottir; Rachel Nusbaum; Gillian Hooker; Suzanne C O'Neill; Lina Jandorf; Scott P Kelly; Jessica Heinzmann; Sarah Kelleher; Elizabeth Poggi; Marc D Schwartz
Journal:  Breast Cancer Res Treat       Date:  2020-01-01       Impact factor: 4.872

4.  Do cancer risk and benefit-harm ratios influence women's consideration of risk-reducing mastectomy? A scenario-based experiment in five European countries.

Authors:  Felix G Rebitschek; Nora Pashayan; Martin Widschwendter; Odette Wegwarth
Journal:  PLoS One       Date:  2019-06-12       Impact factor: 3.240

Review 5.  Population genomic screening: Ethical considerations to guide age at implementation.

Authors:  Scott J Spencer; Stephanie M Fullerton
Journal:  Front Genet       Date:  2022-10-04       Impact factor: 4.772

6.  Second primary breast cancer after unilateral mastectomy alone or with contralateral prophylactic mastectomy.

Authors:  Shailesh Agarwal; Lisa Pappas; Cindy B Matsen; Jayant P Agarwal
Journal:  Cancer Med       Date:  2020-09-12       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.